Prevalence of ultrasound-diagnosed non-alcoholic fatty liver disease in a hospital cohort and its association with anthropometric, biochemical and sonographic characteristics

International Journal of Clinical and Experimental Medicine

Volumn 3, Issue 3, 2010, Pages 202-210

  Kirovski, Georgi ^a   Schacherer, Doris ^a   Wobser, Hella ^a   Huber, Hanna ^a   Niessen, Christoph ^a   Beer, Catrin ^a   Schölmerich, Jürgen ^a   Hellerbrand, Claus ^a  

^a UNIVERSITY HOSPITAL REGENSBURG   (Germany)

Author keywords

Diagnosis; Non alcoholic fatty liver disease (NAFLD); Obesity; Prospective study; Risk factor; Ultrasound

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTHROPOMETRY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BODY MASS; CHEMICAL ANALYSIS; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DIABETES MELLITUS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; ECHOGRAPHY; FEMALE; GERMANY; HOSPITAL PATIENT; HUMAN; HYPERTENSION; INTERDISCIPLINARY COMMUNICATION; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; OBESITY; PATIENT REFERRAL; PATIENT SELECTION; PORTAL VEIN BLOOD FLOW; PREVALENCE; RISK ASSESSMENT; RISK FACTOR; WAIST HIP RATIO;

EID: 77956076765     PISSN: None     EISSN: 19405901     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Neuschwander-Tetri BA and Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology 2003; 37: 1202-1219.
2. [2]. Clark JM. The epidemiology of nonalcoholic fatty liver disease in adults. J Clin Gastroenterol 2006; 40 Suppl 1: S5-10.
3. Bedogni G, Miglioli L, Masutti F, Tiribelli C, Marchesini G, and Bellentani S. Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study. Hepatology 2005; 42: 44-52.
4. Amarapurkar DN, Hashimoto E, Lesmana LA, Sollano JD, Chen PJ, and Goh KL. How common is non-alcoholic fatty liver disease in the Asia- Pacific region and are there local differences? J Gastroenterol Hepatol 2007; 22: 788-793.
5. Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC, Grundy SM, and Hobbs HH. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004; 40: 1387-1395.
6. Zelber-Sagi S, Nitzan-Kaluski D, Halpern Z, and Oren R. Prevalence of primary non-alcoholic fatty liver disease in a population-based study and its association with biochemical and anthropometric measures. Liver Int 2006; 26: 856-863.
7. [7]. Chen CH, Huang MH, Yang JC, Nien CK, Yang CC, Yeh YH, and Yueh SK. Prevalence and risk factors of nonalcoholic fatty liver disease in an adult population of taiwan: metabolic significance of nonalcoholic fatty liver disease in nonobese adults. J Clin Gastroenterol 2006; 40: 745- 752.
8. Dassanayake AS, Kasturiratne A, Rajindrajith S, Kalubowila U, Chakrawarthi S, De Silva AP, Makaya M, Mizoue T, Kato N, Wickremasinghe AR, and de Silva HJ. Prevalence and risk factors for non-alcoholic fatty liver disease among adults in an urban Sri Lankan population. J Gastroenterol Hepatol 2009; 24: 1284-1288.
9. Fan JG, Zhu J, Li XJ, Chen L, Li L, Dai F, Li F, and Chen SY. Prevalence of and risk factors for fatty liver in a general population of Shanghai, China. J Hepatol 2005; 43: 508-514.
10. Zhou YJ, Li YY, Nie YQ, Ma JX, Lu LG, Shi SL, Chen MH, and Hu PJ. Prevalence of fatty liver disease and its risk factors in the population of South China. World J Gastroenterol 2007; 13: 6419-6424.
11. Brunt EM. Nonalcoholic steatohepatitis. Semin Liver Dis 2004; 24: 3-20.
12. Marchesini G, Brizi M, Morselli-Labate AM, Bianchi G, Bugianesi E, McCullough AJ, Forlani G, and Melchionda N. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med 1999; 107: 450-455.
13. Hauner H, Bramlage P, Losch C, Steinhagen-Thiessen E, Schunkert H, Wasem J, Jockel KH, and Moebus S. Prevalence of obesity in primary care using different anthropometric measures-- results of the German Metabolic and Cardiovascular Risk Project (GEMCAS). BMC Public Health 2008; 8: 282.
14. Fan JG and Farrell GC. VAT fat is bad for the liver, SAT fat is not! J Gastroenterol Hepatol 2008; 23: 829-832.
15. van der Poorten D, Milner KL, Hui J, Hodge A, Trenell MI, Kench JG, London R, Peduto T, Chisholm DJ, and George J. Visceral fat: a key mediator of steatohepatitis in metabolic liver disease. Hepatology 2008; 48: 449-457.
16. Kim HJ, Cho MH, Park JS, Nam JS, Kang ES, Ahn CW, Cha BS, Lee EJ, Lim SK, Kim KR, Lee HC, and Huh KB. Visceral fat thickness predicts fatty liver in Koreans with type 2 diabetes mellitus. J Korean Med Sci 2008; 23: 256-261.
17. Lirussi F, Vitturi N, Azzalini L, Orando S, Orlando R, Plebani M, and Realdi G. Perihepatic adipose tissue thickness: a new non-invasive marker of NAFLD?. J Gastrointestin Liver Dis 2009; 18: 61-66.
18. Park BJ, Kim YJ, Kim DH, Kim W, Jung YJ, Yoon JH, Kim CY, Cho YM, Kim SH, Lee KB, Jang JJ, and Lee HS. Visceral adipose tissue area is an independent risk factor for hepatic steatosis. J Gastroenterol Hepatol 2008; 23: 900-907.
19. Balci A, Karazincir S, Sumbas H, Oter Y, Egilmez E, and Inandi T. Effects of diffuse fatty infiltration of the liver on portal vein flow hemodynamics. J Clin Ultrasound 2008; 36: 134-140.
20. Erdogmus B, Tamer A, Buyukkaya R, Yazici B, Buyukkaya A, Korkut E, Alcelik A, and Korkmaz U. Portal vein hemodynamics in patients with non-alcoholic fatty liver disease. Tohoku J Exp Med 2008; 215: 89-93.
21. Falck-Ytter Y, Younossi ZM, Marchesini G, and McCullough AJ. Clinical features and natural history of nonalcoholic steatosis syndromes. Semin Liver Dis 2001; 21: 17-26.
22. Targher G, Bertolini L, Padovani R, Rodella S, Arcaro G, and Day C. Differences and similarities in early atherosclerosis between patients with non-alcoholic steatohepatitis and chronic hepatitis B and C. J Hepatol 2007; 46: 1126-1132.
23. Targher G, Bertolini L, Rodella S, Lippi G, Franchini M, Zoppini G, Muggeo M, and Day CP. NASH predicts plasma inflammatory biomarkers independently of visceral fat in men. Obesity (Silver Spring) 2008; 16: 1394-1399.
24. Hezode C, Lonjon I, Roudot-Thoraval F, Mavier JP, Pawlotsky JM, Zafrani ES, and Dhumeaux D. Impact of smoking on histological liver lesions in chronic hepatitis C. Gut 2003; 52: 126-129.
25. Pessione F, Ramond MJ, Njapoum C, Duchatelle V, Degott C, Erlinger S, Rueff B, Valla DC, and Degos F. Cigarette smoking and hepatic lesions in patients with chronic hepatitis C. Hepatology 2001; 34: 121-125.
26. Zein CO, Beatty K, Post AB, Logan L, Debanne S, and McCullough AJ. Smoking and increased severity of hepatic fibrosis in primary biliary cirrhosis: A cross validated retrospective assessment. Hepatology 2006; 44: 1564-1571.
27. Dev A, Patel K, Conrad A, Blatt LM, and McHutchison JG. Relationship of smoking and fibrosis in patients with chronic hepatitis C. Clin Gastroenterol Hepatol 2006; 4: 797-801.
28. Rankin EB, Rha J, Selak MA, Unger TL, Keith B, Liu Q, and Haase VH. Hypoxia-inducible factor 2 regulates hepatic lipid metabolism. Mol Cell Biol 2009; 29: 4527-4538.
29. Fracanzani AL, Valenti L, Bugianesi E, Andreoletti M, Colli A, Vanni E, Bertelli C, Fatta E, Bignamini D, Marchesini G, and Fargion S. Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes. Hepatology 2008; 48: 792-798.
30. Wong VW, Hui AY, Tsang SW, Chan JL, Tse AM, Chan KF, So WY, Cheng AY, Ng WF, Wong GL, Sung JJ, and Chan HL. Metabolic and adipokine profile of Chinese patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2006; 4: 1154-1161.
31. Sorbi D, Boynton J, and Lindor KD. The ratio of aspartate aminotransferase to alanine aminotransferase: potential value in differentiating nonalcoholic steatohepatitis from alcoholic liver disease. Am J Gastroenterol 1999; 94: 1018-1022.
32. Nanji AA, French SW, and Freeman JB. Serum alanine aminotransferase to aspartate aminotransferase ratio and degree of fatty liver in morbidly obese patients. Enzyme 1986; 36: 266-269.
33. Arkan MC, Hevener AL, Greten FR, Maeda S, Li ZW, Long JM, Wynshaw-Boris A, Poli G, Olefsky J, and Karin M. IKK-beta links inflammation to obesity-induced insulin resistance. Nat Med 2005; 11: 191-198.
34. Cai D, Yuan M, Frantz DF, Melendez PA, Hansen L, Lee J, and Shoelson SE. Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat Med 2005; 11: 183-190.